<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150420</url>
  </required_header>
  <id_info>
    <org_study_id>ST-001</org_study_id>
    <nct_id>NCT03150420</nct_id>
  </id_info>
  <brief_title>A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients</brief_title>
  <acronym>CALISTA</acronym>
  <official_title>A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hope Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate&#xD;
      the efficacy and safety of intravenous Sodium Thiosulfate Injection for treatment of acute&#xD;
      calciphylaxis-associated pain in chronic hemodialysis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial will&#xD;
      evaluate the efficacy and safety of intravenous Sodium Thiosulfate Injection for treatment of&#xD;
      acute calciphylaxis-associated pain in chronic hemodialysis patients. Acute calciphylaxis-&#xD;
      associated pain intensity will be the primary outcome measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to accrue subjects that met the exclusion criterion &quot;Any prior (within the past 30&#xD;
    days) or current Sodium Thiosulfate treatment&quot;.&#xD;
  </why_stopped>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Actual">April 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with 30% improvement in pain severity</measure>
    <time_frame>randomization to 3 weeks</time_frame>
    <description>To compare the effects of treatment with intravenous Sodium Thiosulfate Injection vs. placebo for the proportion of patients (responders) who achieve a ≥ 30% reduction based upon pain intensity score (modified BPI/SF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint-a: Number of patients with stabilization or improvement in calciphylaxis skin lesions.</measure>
    <time_frame>randomization to 3 weeks</time_frame>
    <description>Proportion of patients who achieve improvement or stabilization (i.e., not worsening) of skin lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint-b: Occurence of surgical debridement of skin lesions and/or amputation.</measure>
    <time_frame>during week 3</time_frame>
    <description>Occurence of surgical debridement of skin lesions and/or amputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint-c: Occurrence of surgical debridement of skin lesions and/or amputation.</measure>
    <time_frame>randomization to 3 weeks</time_frame>
    <description>Occurrence of surgical debridement of skin lesions and/or amputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint-d: Time to achieve ≥ 30% improvement in pain severity</measure>
    <time_frame>randomization to 3 weeks</time_frame>
    <description>Time in days when a patient achieves a ≥ 30% improvement based upon pain intensity score (modified BPI/SF).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Calciphylaxis</condition>
  <arm_group>
    <arm_group_label>Sodium Thiosulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Thiosulfate Injection (25 grams sodium thiosulfate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride injection, USP (normal saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks</description>
    <arm_group_label>Sodium Thiosulfate</arm_group_label>
    <other_name>Intravenous Sodium Thiosulfate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Normal Saline</intervention_name>
    <description>Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks</description>
    <arm_group_label>Placebo-Normal Saline</arm_group_label>
    <other_name>0.9% sodium chloride solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed of the investigational nature of the study and sign written informed consent&#xD;
&#xD;
          -  Willing and able to adhere to all study-related procedures, including adherence to&#xD;
             study medication regimen&#xD;
&#xD;
          -  Male or female ≥18 years old&#xD;
&#xD;
          -  End-stage renal disease on chronic hemodialysis&#xD;
&#xD;
          -  Calciphylaxis with active skin lesion(s) of any morphological appearance (including&#xD;
             but not limited to livedo, induration, ulceration, etc.) and tissue histology review&#xD;
             consistent with calciphylaxis diagnosis. Histological features consistent with&#xD;
             calciphylaxis will include soft tissue calcification, microthrombosis, and/or&#xD;
             fibrointimal hyperplasia of dermal arterioles&#xD;
&#xD;
          -  Acute pain associated with calciphylaxis lesions pain intensity score of ≥ 5 at&#xD;
             initial screening on the modified BPI/SF scale&#xD;
&#xD;
          -  Women of childbearing potential must have a pregnancy test (urine or serum [if&#xD;
             anuric]) at screening and not be pregnant and willing to use an acceptable method of&#xD;
             contraception for the entire duration of the study (3 weeks)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peritoneal dialysis patients&#xD;
&#xD;
          -  Current congestive heart failure exacerbation&#xD;
&#xD;
          -  Baseline abnormalities related to QT prolongation (corrected QT interval &gt; 470 ms),&#xD;
             hypocalcemia (serum albumin-corrected calcium &lt; 8 mg/dL ), metabolic acidosis (serum&#xD;
             bicarbonate &lt; 18 mmol/L, hypotension (resting systolic blood pressure while seated &lt;&#xD;
             80), or interdialytic weight gain ≥ 4.0 kg&#xD;
&#xD;
          -  History of ventricular arrhythmias including ventricular fibrillation or ventricular&#xD;
             tachycardia associated with shortness of breath, dizziness, hypotension, or syncope&#xD;
&#xD;
          -  Any prior (within the past 30 days) or current intravenous Sodium Thiosulfate&#xD;
             Injection treatment&#xD;
&#xD;
          -  Other investigational agent (drug, biologic, or device) study within the past 30 days&#xD;
             and/or for the duration of the trial&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History of allergy to sulfites, thiosulfate, or any component in Sodium Thiosulfate&#xD;
             Injection (sulfa allergy is not an exclusion criterion)&#xD;
&#xD;
          -  Significant other acute or chronic concomitant diseases (including but not limited to&#xD;
             hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema,&#xD;
             pulmonary embolism) that would be inconsistent with survival for at least 3 months&#xD;
&#xD;
          -  Other serious concurrent or recent medical or psychiatric condition which, in the&#xD;
             opinion of the Investigator, makes the patient unsuitable for participation in this&#xD;
             study&#xD;
&#xD;
          -  Ongoing application of dialysate admixed with iron salt e.g. ferric pyrophosphate&#xD;
             during the entire trial period (patients who are on dialysate admixed with iron salt&#xD;
             at screening are eligible if dialysate admixed with iron salt can be substituted with&#xD;
             non-iron based dialysate and patients can be maintained on non-iron based dialysate&#xD;
             therapy for the entire duration of trial period)&#xD;
&#xD;
          -  Recent (within 1 week) history of surgical parathyroidectomy or scheduled for surgical&#xD;
             parathyroidectomy during the course of the study&#xD;
&#xD;
          -  History of opioid addiction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Sherman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hope Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Icahn School of Medicine at Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Medical Center</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2W 1S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre Winnipeg</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2V 3M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>calciphylaxis</keyword>
  <keyword>calcific uremic arteriolopathy, calcinosis</keyword>
  <keyword>calcium metabolism disorders</keyword>
  <keyword>metabolic diseases</keyword>
  <keyword>sodium thiosulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

